Approval · Notice of Compliance 33449 · 2024
GABAPENTIN: Notice of Compliance 33449
Issued June 14, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33449
- Date
- June 14, 2024
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GABAPENTIN | 02548763 | Approved |
| GABAPENTIN | 02548771 | Approved |
| GABAPENTIN | 02548798 | Approved |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP